Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).
The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.
Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.
Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...
The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was ...
Here are some of the major companies whose stocks moved on the week’s news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback